--- title: "60 Degrees Pharmaceuticals (SXTP) news: going concern" url: "https://aibio.space/companies/60-degrees-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SXTP going concern and offering news: 60 Degrees Pharmaceuticals closes private placement for about $1.0 million gross proceeds." --- SXTP 60 Degrees Pharmaceuticals, Inc. NASDAQ · United States # 60 Degrees Pharmaceuticals (SXTP) news SXTP going concern and offering news Company Updates · 2026-10-27 ## [60 Degrees reports PCR-negative results in five babesiosis patients](https://aibio.space/news/60-degrees-reports-pcr-negative-results-five-babesiosis-patients/) All five patients who finished the expanded access study reported improved outcomes and negative conventional PCR tests, and four of five were also negative on a highly sensitive test. ## Latest 60 Degrees Pharmaceuticals news 1. 2026-10-06 Company Updates [60 Degrees outlines next steps after its babesiosis hospital study interim analysis](https://aibio.space/news/60-degrees-outlines-next-steps-after-babesiosis-hospital-study-interim/) At an October 6, 2026 webinar, the company said 30 patients were enrolled in its hospital study and that it plans to complete the current dataset and move to unblinding. 2. 2026-09-12 Company Updates [60 Degrees seeks FDA priority voucher for tafenoquine in babesiosis](https://aibio.space/news/60-degrees-seeks-fda-priority-voucher-tafenoquine-babesiosis/) A September 12, 2026 submission asks FDA for a Commissioner's National Priority Voucher for an efficacy supplement to ARAKODA in babesiosis. 3. 2026-09-08 Financings [60 Degrees presents its July financing and cash runway to investors](https://aibio.space/news/60-degrees-presents-july-financing-cash-runway-investors/) A September 2026 investor presentation lists a $1.0M July 31 private placement, about $1.0M of cash at June 30, 2026, and a runway the slide dates to early October 2026. 4. 2026-08-04 Financings [60 Degrees Pharmaceuticals closes private placement for about $1.0 million gross proceeds](https://aibio.space/news/60-degrees-pharmaceuticals-closes-private-placement-about-1-0-million/) 60 Degrees sold shares at $1.74 for approximately $1.0 million gross, with H.C. Wainwright & Co. as exclusive placement agent, after its annual report carried a going-concern warning. 5. 2026-07-20 Company Updates [60 Degrees describes its babesiosis plan and a 2028 profitability target](https://aibio.space/news/60-degrees-describes-babesiosis-plan-2028-profitability-target/) A July 2026 corporate presentation says the company targets profitability in 2028, based on malaria prevention sales and a supplemental indication for babesiosis. 6. 2025-07-18 Financings [60 Degrees Pharmaceuticals prices $5 million offering, with warrants for $5 million more](https://aibio.space/news/60-degrees-pharmaceuticals-prices-5-million-offering-warrants-5/) 60 Degrees Pharmaceuticals priced 2,631,578 shares at $1.90 with warrants. About $5 million comes in up front, and the short-term warrants could bring in about $5 million more only if fully exercised for cash. 7. 2025-02-06 Financings [60 Degrees Pharmaceuticals sells 1,503,500 shares in $1.075 million registered direct offering](https://aibio.space/news/60-degrees-pharmaceuticals-sells-1-503-500-shares-1-075-million/) 60 Degrees Pharmaceuticals sold 1,503,500 shares at $0.715 each in a registered direct offering that closed Feb 6, 2025. H.C. Wainwright was the placement agent, and the company reports about $908,627 of net proceeds, with matching warrants at $0.59. ## 60 Degrees Pharmaceuticals at a glance - **Ticker**: SXTP - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $1.0 million ### Related companies - [IGC Pharma](https://aibio.space/companies/igc-pharma/) AMEX: IGC - [Xeris Biopharma Holdings](https://aibio.space/companies/xeris-biopharma/) NASDAQ: XERS - [CalciMedica](https://aibio.space/companies/calcimedica/) NASDAQ: CALC - [Cadrenal Therapeutics](https://aibio.space/companies/cadrenal-therapeutics/) NASDAQ: CVKD - [Enliven Therapeutics](https://aibio.space/companies/enliven-therapeutics/) NASDAQ: ELVN - [Disc Medicine](https://aibio.space/companies/disc-medicine/) NASDAQ: IRON - [REBUS HLDGS INC.](https://aibio.space/companies/rebus-hldgs/) OTC: RBSH - [Kyverna Therapeutics](https://aibio.space/companies/kyverna-therapeutics/) NASDAQ: KYTX ### Also on NASDAQ - [Tvardi Therapeutics](https://aibio.space/companies/tvardi-therapeutics/) TVRD - [Caris Life Sciences](https://aibio.space/companies/caris-life-sciences/) CAI - [Q32 Bio](https://aibio.space/companies/q32-bio/) QTTB - [Lyell Immunopharma](https://aibio.space/companies/lyell-immunopharma/) LYEL - [Lantern Pharma](https://aibio.space/companies/lantern-pharma/) LTRN - [SNDL](https://aibio.space/companies/sndl/) SNDL ## 60 Degrees Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$1.0 million](https://www.sec.gov/Archives/edgar/data/1946563/000155485526000467/) | [$607,574](https://www.sec.gov/Archives/edgar/data/1946563/000155485526000467/) | | Research and development | [$2.1 million](https://www.sec.gov/Archives/edgar/data/1946563/000155485526000467/) | [$5.0 million](https://www.sec.gov/Archives/edgar/data/1946563/000155485526000467/) | | Net income (loss) | [-$7.4 million](https://www.sec.gov/Archives/edgar/data/1946563/000155485526000467/) | [-$7.9 million](https://www.sec.gov/Archives/edgar/data/1946563/000155485526000467/) | | Cash from operations | [-$6.8 million](https://www.sec.gov/Archives/edgar/data/1946563/000155485526000467/) | [-$5.6 million](https://www.sec.gov/Archives/edgar/data/1946563/000155485526000467/) | | Cash and equivalents | [$1.5 million](https://www.sec.gov/Archives/edgar/data/1946563/000155485526001860/) | [$1.7 million](https://www.sec.gov/Archives/edgar/data/1946563/000155485526000467/) | | Short-term investments | [$1.2 million](https://www.sec.gov/Archives/edgar/data/1946563/000155485526001860/) | [$1.7 million](https://www.sec.gov/Archives/edgar/data/1946563/000155485526000467/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $1.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about 60 Degrees Pharmaceuticals Has 60 Degrees Pharmaceuticals issued a going-concern warning? Our latest story on this, dated Aug 4, 2026: "60 Degrees Pharmaceuticals closes private placement for about $1.0 million gross proceeds". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/60-degrees-pharmaceuticals-closes-private-placement-about-1-0-million/). Has 60 Degrees Pharmaceuticals raised money recently? Our latest story on this, dated Sep 8, 2026: "60 Degrees presents its July financing and cash runway to investors". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/60-degrees-presents-july-financing-cash-runway-investors/). What is the ticker symbol of 60 Degrees Pharmaceuticals? 60 Degrees Pharmaceuticals, Inc. trades under the ticker SXTP on NASDAQ. Where is 60 Degrees Pharmaceuticals listed? 60 Degrees Pharmaceuticals, Inc. is listed on NASDAQ. What is the SEC CIK of 60 Degrees Pharmaceuticals? The SEC Central Index Key (CIK) for 60 Degrees Pharmaceuticals, Inc. is 1946563. Its filings are on SEC EDGAR. How many shares does 60 Degrees Pharmaceuticals have outstanding? 3,516,988 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is 60 Degrees Pharmaceuticals listed under? Our directory records 60 Degrees Pharmaceuticals, Inc. under United States. What does 60 Degrees Pharmaceuticals do? Our directory classifies 60 Degrees Pharmaceuticals, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of 60 Degrees Pharmaceuticals? The ISIN recorded for 60 Degrees Pharmaceuticals, Inc. is US83006G5009. Does aibio.space cover 60 Degrees Pharmaceuticals? aibio.space lists 60 Degrees Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is 60 Degrees Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What was 60 Degrees Pharmaceuticals's revenue last year? $1.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is 60 Degrees Pharmaceuticals profitable? 60 Degrees Pharmaceuticals, Inc. reported a net loss of $7.4 million for the fiscal year ended Dec 31, 2025, and used $6.8 million of cash in operations, per its annual report to the SEC. How much does 60 Degrees Pharmaceuticals spend on research and development? $2.1 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does 60 Degrees Pharmaceuticals have? $1.0 million in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: 60 Degrees Pharmaceuticals Members talk about 60 Degrees Pharmaceuticals (SXTP). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at 60 Degrees Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-09-08 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1946563/000121390026098056/ea030486201ex99-1.htm) 2. 2026-08-06 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1946563/000121390026086136/ea0300977-8k_60degrees.htm) 3. 2026-07-02 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1946563/000121390026074961/ea0296941-def14a_60degrees.htm) 4. 2026-06-08 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1946563/000121390026066363/ea0292597-pre14a_60degrees.htm) 5. 2026-03-13 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1946563/000121390026027756/ea0281691-8k_60degrees.htm) 6. 2026-02-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1946563/000121390026015239/ea0276747-8k_60degrees.htm) 7. 2026-01-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01). [Source](https://www.sec.gov/Archives/edgar/data/1946563/000121390026007330/ea0273809-8k_60degrees.htm) 8. 2026-01-21 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1946563/000121390026006179/ea027344001ex99-1_60degrees.htm) 9. 2025-10-10 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1946563/000121390025098131/ea0260878-8k_60degrees.htm) 10. 2025-08-27 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1946563/000121390025080878/ea0254708-def14a_60degrees.htm) 11. 2025-08-15 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1946563/000121390025077435/ea0253175-pre14a_60degrees.htm) 12. 2025-07-18 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1946563/000121390025065718/ea024943801ex99-1_60degrees.htm) 13. 2025-07-07 Financings Filed a final prospectus for a securities offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1946563/000121390025061842/ea0248104-s1_60degrees.htm) 14. 2024-11-06 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1946563/000121390024095068/ea022027801-8k_60degrees.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SXTP on TradingView](https://www.tradingview.com/symbols/NASDAQ-SXTP/). ## SEC filings and registration - **SEC name**: 60 Degrees Pharmaceuticals, Inc. - **CIK**: 1946563 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: SXTP (Nasdaq), SXTPW (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 1025 CONNECTICUT AVENUE NW, WASHINGTON, DC, 20036 - **Phone**: 202-327-5422 - **Shares outstanding**: 3,516,988 as of 2026-08-14 (10-Q filed 2026-08-14) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1946563/000121390026106979/ea0307761-8k_60degrees.htm) filed 2026-10-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1946563/000121390026099702/ea0305442-8k_60degree.htm) filed 2026-09-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1946563/000121390026098056/ea0304862-8k_60degrees.htm) filed 2026-09-08 - [S-3](https://www.sec.gov/Archives/edgar/data/1946563/000121390026090125/ea0301426-s3_60degrees.htm) filed 2026-08-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1946563/000155485526001860/sxtp-20260630.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1946563/000121390026086136/ea0300977-8k_60degrees.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1946563/000121390026085235/ea0300260-8k_60degrees.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1946563/000121390026079612/ea0298505-8k_60degrees.htm) filed 2026-07-20 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001946563), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details 60 Degrees Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SXTP, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: 60 Degrees Pharmaceuticals, Inc. - **Ticker**: SXTP - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US83006G5009 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SXTP/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/60-degrees-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "60 Degrees Pharmaceuticals (SXTP) news: going concern", 2026-10-31, https://aibio.space/companies/60-degrees-pharmaceuticals/